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Abstract: Restless legs syndrome (RLS) is a common neurological disorder characterized by 
an irresistible urge to move the legs, usually accompanied or caused by uncomfortable sensa-
tions in the legs. Symptoms are worse in the evening or at night than during the day and gener-
ally begin or worsen during periods of rest or inactivity. The chronic sleep disturbance often 
associated with RLS is likely due, at least in part, to the circadian nature of the symptoms. The 
relationship between disturbed sleep and reduced daytime functioning is well known and thus 
the accurate diagnosis and effective management of RLS is imperative.
Keywords: restless legs syndrome, RLS, sleep disturbance, reduced daytime functioning, 
circadian
Introduction
Restless legs syndrome (RLS) is a chronic neurological disorder that is estimated 
to affect up to 10% of adults in the US (Phillips et al 2000; Ulfberg et al 2001a, 
2001b). RLS occurs as two forms, a primary disorder independent of any other 
disease, and secondary, in which symptoms are triggered by another condition such 
as end-stage renal disease (ESRD), iron deﬁ  ciency, and normal pregnancy (Allen 
and Earley 2001).
RLS is characterized by an irresistible urge to move the legs, usually accompanied 
or caused by uncomfortable sensations in the legs. The symptoms generally begin or 
worsen during periods of rest or inactivity, are partially or totally relieved by move-
ment (at least as long as the activity continues) and are worse in the evening or at night 
than during the day. In addition to these symptoms that are required for diagnosis, 
approximately 80% of patients with RLS experience periodic leg movements (PLMs) 
during sleep or while awake (Montplaisir et al 1997).
Many studies have demonstrated that sleep disturbances are a key consequence, and 
often the most troublesome symptom, of RLS. Thus, sleep problems are commonly 
reported by patients with both primary and secondary RLS (Walker et al 1995; Suzuki 
et al 2003; Hening et al 2004; Rijsman et al 2004a). In addition, virtually all patients 
seeking treatment for RLS report that they have disturbed sleep (Allen et al 2003). 
Furthermore, in a large survey of the general population in Norway and Denmark, both 
insomnia and excessive daytime sleepiness were signiﬁ  cant predictors of the presence 
of diagnostic symptoms of RLS (Bjorvatn et al 2005).
Sleep is a fundamental regulatory process of the nervous system, and the need 
for sleep is a powerful homeostatic drive. Lack of sleep, resulting from insomnia, 
has many consequences, including reduced quality of life and social functioning, 
impaired work performance, impaired memory and cognitive functioning, and 
increased healthcare utilization (Simon and VonKorff 1997; NIH 2005). Thus, it is 
important that sleep disturbances associated with RLS are identiﬁ  ed and managed as 
effectively as possible.Neuropsychiatric Disease and Treatment 2006:2(4) 514
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Effects of RLS on patients’ sleep
Effects in patients with primary RLS
In a large (n=1485 respondents), single-center, population-
based study in The Netherlands (conducted before the key 
diagnostic symptoms of RLS were published), a positive 
answer to the question “Is your sleep disturbed by leg move-
ments?” was considered to indicate the presence of RLS. 
Overall, 7.1% of respondents answered “Often” or “Always” 
to this question, and were considered to have some symptoms 
of RLS (Rijsman et al 2004a). Those positive respondents 
reported more difﬁ  culties in initiating sleep, experienced 
more awakenings during the night and less recuperative 
sleep, were more tired, and took more naps during the day 
than those without RLS. However, because of the non-
speciﬁ  c nature of the one diagnostic question used in this 
survey, these sleep disturbances might have resulted partly 
or wholly from PLMs rather than the symptoms of RLS in 
this population.
The recently published National Sleep Foundation poll 
(Phillips et al 2006) (1506 US adults) asked respondents 
how often, in the past year, they had experienced unpleasant 
feelings in their legs at night with an urge to move when 
lying down to sleep. A total of 9.7% of those answering 
reported having these symptoms at least a few nights per 
week and that the feelings were worse in the evening or 
at night than at other times of the day, thus meeting the 
authors’ criteria for RLS. This group was more likely to 
stay up longer than planned for more than a few nights per 
week, take more than 30 minutes to fall asleep, sleep for 
less than 6 hours per night, have body twitches–movements 
during the night and report symptoms of insomnia, than 
those not at risk of RLS (p0.05 for all). Furthermore, 
those at risk of RLS were also more likely to report daytime 
fatigue (55% of respondents) and problems of daytime 
functioning, including being late to or missing work, making 
errors at work, missing events, and driving while drowsy 
(p0.05 for all).
Another large (n=23 052), multinational, study of 
patients in primary care described a group of patients 
who experienced all four diagnostic symptoms of RLS 
at least twice weekly, with these symptoms having some 
negative impact on their quality of life (n=551) (Hening 
et al 2004). Most of these patients (88%) reported at least 
one sleep-related symptom along with the symptoms of 
RLS, and 43% of patients rated a sleep-related symp-
tom as their most troublesome. In addition, when these 
patients had symptoms of RLS, 69% of them took more 
than 30 minutes to fall asleep and 60% reported waking 
three or more times per night. A similar study (n=16202) 
identiﬁ  ed a group of patients with the diagnostic symptoms 
of RLS from general-population surveys in six countries 
(Allen et al 2005). Of the patients with at least twice-
weekly symptoms that caused moderate distress (n=416), 
38% reported that problems related to sleep disturbance 
were their most troublesome symptoms. In addition, 61% 
reported disturbed or interrupted sleep, 48% reported an 
inability to fall asleep, and around 40% of patients reported 
that they had insufﬁ  cient sleep.
Two population surveys conducted in Sweden have 
investigated the prevalence of RLS and its impact on other 
complaints including sleep disturbance. In a survey of men 
(n=4000), sleep complaints were more frequent among those 
who met the diagnostic criteria for RLS, than those who 
did not (Ulfberg et al 2001a). The odds ratio (OR) for not 
being refreshed at awakening was 3.8 (95% CI 2.8–5.3) for 
those with RLS. In addition, those men with RLS reported 
more problems in initiating and maintaining sleep, and more 
disturbed sleep. Similar problems of insomnia were also 
reported from a survey of women (n=200) from the same 
region (Ulfberg et al 2001b). The OR for not being refreshed 
at awakening was 4.7 (95% CI 1.5–14.8) for women with 
symptoms of RLS.
In addition to these surveys of people in the general 
population who have symptoms of RLS, polysomnographic 
(PSG) studies of patients with RLS have shown that patients 
with RLS demonstrated detrimental effects on sleep. These 
patients had a reduced total sleep time (mean 326.3 minutes) 
compared with controls (383.3 minutes); reduced sleep 
efﬁ  ciency (mean 73.2% vs 86.6%); and showed increased 
numbers of awakenings (mean 12.2 vs 7.4). They also showed 
a reduction in subjective sleep quality and efﬁ  cacy (measured 
using the Pittsburgh Sleep Quality Index), compared with 
those without RLS (Saletu et al 2002a).
Effects in patients with secondary RLS
Sleep disturbance and symptoms of RLS are common in 
patients with ESRD who are undergoing dialysis (Walker 
et al 1995). In a survey of 54 patients undergoing dialysis, 
57% reported symptoms of RLS, and most of these patients 
reported symptoms of sleep disturbance (Walker et al 1995). 
Three quarters of these patients complained of daytime 
sleepiness, 48% believed that symptoms of RLS caused 
delayed sleep onset, and 42% stated that these symptoms 
caused frequent awakenings.Neuropsychiatric Disease and Treatment 2006:2(4) 515
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In a large (n=333) study of patients undergoing dialysis, 
that used questions based on the diagnostic symptoms of 
RLS, 14% of patients were identiﬁ  ed as meeting these diag-
nostic criteria (Mucsi et al 2005). Compared with patients 
who did not have RLS, these patients were twice as likely to 
have clinically signiﬁ  cant insomnia (deﬁ  ned as a score of at 
least 10 on the Athens Insomnia Scale) and more frequently 
reported speciﬁ  c sleep problems, such as problems with sleep 
initiation and sleep fragmentation. Another survey of patients 
undergoing dialysis showed that 70% of patients with ESRD 
reported the diagnostic symptoms of RLS (Hui et al 2002). 
Almost all of those patients also reported sleep disturbance, 
such as sleep-onset and sleep-maintenance insomnia, and 
daytime sleepiness.
Sleep problems are also common in pregnancy. A large 
(n=16528) survey of pregnant women was conducted in 
Japan to assess the prevalence of RLS in these women and 
its relationship to sleep problems (Suzuki et al 2003). RLS 
(assessed using one question about the presence of pares-
thesias) was present in 20% of women, and was associated 
with a reduction in sleep duration, difﬁ  culties in initiating 
and maintaining sleep, early-morning waking, and excessive 
daytime sleepiness.
The relationship between RLS 
and PLMs
A large proportion of patients with RLS also experience large 
numbers of PLMs (an incidence of more than ﬁ  ve PLMs per 
hour of sleep – PLM index [PLM-I] – is considered greater 
than normal). However, the relationship between the presence 
of PLMs and sleep disturbances is unclear.
In a PSG study of 133 patients with RLS, 80% had a 
PLM-I that was greater than 5 (mean PLM-I was 28.9; 
the index of periodic leg movements during the wake 
time – PLMW-I – was similar at 29.3) (Montplaisir et al 
1997). Most of these patients reported in a questionnaire 
that they had difﬁ  culty falling asleep and maintaining 
sleep because of RLS symptoms. However, there was no 
correlation between the PLM index and either the number 
of awakenings or sleep efﬁ  ciency. These results suggest 
that PLMs are not a major cause of sleep disruption in 
RLS. This conclusion is supported by data from a large 
(n = 1124) retrospective review of patients undergoing 
PSG for assessment of sleep-disordered breathing (SDB, 
an umbrella term that covers a spectrum of common sleep-
related respiratory disorders), which is often associated 
with PLMs (Chervin 2001). In that study, neither daytime 
sleepiness (assessed by multiple sleep latency tests) nor 
subjective sleep problems were associated with the pres-
ence of PLMs. In addition, in a study of patients with RLS, 
a reduction in subjective sleep quality was signiﬁ  cantly 
correlated with the PLM-I on the ﬁ  rst but not the second 
night of testing (Hornyak et al 2004). The authors account 
for this correlation in the ﬁ  rst night of testing as an adap-
tation effect to the PSG protocol, probably resulting in 
more superﬁ  cial sleep and heightened perception on the 
ﬁ  rst night of testing.
On the other hand, other authors have reported that 
PLMs are associated with significant levels of sleep 
disturbance. EEG monitoring has shown that even when 
PLMs are not associated with microarousals or full 
awakening, they almost always produce EEG activation 
and changes in heart rate (Sforza et al 1999). Possible 
effects of PLMs were also reported in a PSG study of 
33 patients with RLS (who had a mean PLM-I of 49) and 
26 patients with PLM disorder (experienced as PLMs 
only, rather than the sensory and motor symptoms that are 
characteristic of RLS; PLM-I was 46). Patients with RLS 
showed reduced total sleep time and sleep efﬁ  ciency and 
increased wakefulness during the sleep period, compared 
with healthy controls (Saletu et al 2002a). Patients with 
PLM disorder showed an increase in nocturnal awakenings, 
but no changes in other sleep parameters in comparison 
with controls.
Some of these differences in results may be accounted 
for by differences in the etiology of PLMs in different dis-
orders. In SDB, PLMs may be associated with respiratory 
effort (Briellmann et al 1997; Baran et al 2003), whereas 
the etiology of PLMs in RLS may be, at least partly, a con-
sequence of central dopaminergic dysfunction (Allen and 
Earley 2001). In RLS, the sensory and motor symptoms of 
RLS, combined with PLMs, may have more pronounced 
effects on patients’ sleep than either disorder alone. Thus, in 
patients with RLS secondary to renal disease, the presence 
of either RLS or PLMs alone produced detrimental effects 
on sleep parameters (Rijsman et al 2004b). Moreover, the 
combination of both RLS and PLMs produced greater effects 
in reducing sleep quality and efﬁ  cacy, and more complaints 
of insomnia, than in patients without RLS or PLMs, or in 
those patients with only one of these conditions. Likewise, 
in a small study of patients with RLS and PLMs, subjective 
sleep efﬁ  cacy was lower in patients with both disorders than 
in those with PLMs alone (Inoue et al 2002). These results 
indicate that it may be a combination of the symptoms of Neuropsychiatric Disease and Treatment 2006:2(4) 516
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RLS and PLMs that result in greater detrimental effects on 
sleep parameters.
Treatment of the sleep problems 
associated with RLS
Dopaminergic therapies
Dopaminergic drugs are considered the ﬁ  rst-line therapy for 
moderate-to-severe RLS (Silber et al 2004), and these treat-
ments have also been shown to improve sleep disturbances 
in these patients.
Ropinirole has recently been approved for the treatment of 
moderate-to-severe primary RLS in eight countries including 
the USA, France, Switzerland, Australia, and New Zealand. 
This approval followed a large clinical-trial program; three 
key clinical trials of this program – TREAT RLS 1 and 2 
(Therapy with Ropinirole: Efﬁ  cacy And Tolerability in RLS 1 
and 2) and TREAT RLS US – investigated the efﬁ  cacy of 
ropinirole in treating the diagnostic symptoms of primary 
RLS and its associated sleep disturbance (Trenkwalder et al 
2004; Walters et al 2004; Bogan et al 2006). These three 
multicenter, randomized, double-blind, parallel-group, 
placebo-controlled trials involved a total of 932 patients 
with moderate-to-severe primary RLS determined clini-
cally as well as measured by the International Restless Leg 
Scale (IRLS) scale. Patients were treated for 12 weeks with 
ropinirole, 0.25–4 mg/day, or placebo. Ropinirole treatment 
produced statistically signiﬁ  cant improvements, in compari-
son with placebo, in the symptoms of RLS as measured by the 
overall IRLS total score and the proportion of responders on 
the Clinical Global Impression-Improvement (CGI–I) scale. 
In addition, in the TREAT RLS 1 and 2 trials, ropinirole treat-
ment produced statistically signiﬁ  cant improvements on each 
of the four domains assessed on the Medical Outcomes Study 
(MOS) Sleep Scale. Thus, ropinirole treatment produced 
reductions in sleep disturbance and daytime somnolence, and 
increases in sleep adequacy and sleep quantity. Similarly, 
in the TREAT RLS US study, improvements in ropinirole-
treated patients were seen in each of the four domains 
assessed on the MOS Sleep Scale, although the improvement 
did not reach statistical signiﬁ  cance compared with placebo 
for daytime somnolence. Figure 1 shows pooled MOS data 
results from all three trials. In another trial, the maintenance 
of these beneﬁ  cial effects of ropinirole was demonstrated 
out to 9 months of treatment (Karrasch et al 2004). The 
effects of ropinirole on PLMs were assessed in 65 patients 
in the RESET PLM (Ropinirole Efﬁ  cacy and SafEty in the 
Treatment of PLMs) study (Allen et al 2004). Ropinirole, 
compared with placebo, given for 12 weeks was associated 
with a statistically signiﬁ  cant reduction in the PLM-I (from 
48.5 to 11.8), in the number of PLMs producing arousal 
(PLMA-I; from 7.0 to 2.5), and in PLMW-I (from 56.5 to 
23.6). Likewise, in the TREAT RLS US trial, ropinirole, 
compared with placebo, produced a statistically signiﬁ  cant 
reduction in PLM-I (PLM per hour when supine throughout 
the night, measured using actigraphy over 3 nights) from 
39.8 to 15.6 (Bogan et al 2006). The most common adverse 
event during these clinical trials of ropinirole was nausea; 
most adverse events were mild or moderate in severity, and 
their incidence declined over time.
Small studies with the dopamine precursor levodopa 
(L-dopa) have indicated that this drug is effective in the 
management of both the symptoms of and sleep problems 
associated with RLS; and this drug is registered for use in 
the treatment of primary RLS or symptomatic RLS as a 
result of renal impairment requiring dialysis in Germany and 
Switzerland. L-dopa was shown to be effective in improving 
subjective sleep quality and efﬁ  cacy (Montplaisir et al 1986; 
Brodeur et al 1988; Trenkwalder et al 1995; Benes et al 
1999). In addition, L-dopa had some efﬁ  cacy in reducing 
objective (PSG) sleep parameters. In a study of 32 patients, 
L-dopa was associated with a smaller PLM-I compared with 
placebo (45 vs 63) and greater total sleep time (316 minutes 
vs 281 minutes) (Trenkwalder et al 1995). In seven patients, 
L-dopa signiﬁ  cantly improved sleep efﬁ  ciency (from 88.9% 
to 94.4%) (Montplaisir et al 1986). In addition, in a study 
of six patients, L-dopa signiﬁ  cantly reduced sleep latency 
from 9.2 minutes to 3.7 minutes (Brodeur et al 1988). How-
ever, one of the problems associated with L-dopa therapy 
in RLS is its relatively short duration of action, resulting in 
wearing-off of effects during the night (Trenkwalder et al 
1995). This problem can be alleviated by treatment with 
both a regular-release and sustained-release formulation of 
L-dopa. Such a combination treatment has been shown to 
improve subjective sleep parameters – reducing nocturnal 
awakenings and daytime fatigue – and to reduce PLMs 
(Collado-Seidel et al 1999; Saletu et al 2003). Another 
potential problem during long-term L-dopa therapy is 
augmentation of symptoms (earlier onset with an increase 
in severity and the involvement of other limbs), which can 
limit the use of this therapy in a large proportion of patients 
(Allen and Earley 1996). Therefore, in a recent algorithm 
for the treatment of RLS, L-dopa was recommended only 
for the treatment of intermittent RLS, as this infrequent 
use of L-dopa may carry less risk for the development of 
augmentation (Silber et al 2004).Neuropsychiatric Disease and Treatment 2006:2(4) 517
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Some short-term, double-blind, placebo-controlled 
studies of pergolide have demonstrated its efficacy in 
improving the symptoms of RLS, and both subjective and 
objective (PSG) measures of sleep, and on PLMs in patients 
with RLS (Earley et al 1998; Wetter et al 1999). In a study 
of 30 patients, pergolide, in comparison with placebo, was 
associated with greater total sleep time (mean 373.6 minutes 
vs 261.9 minutes) and a reduced PLM-I (5.7 vs 55.0) (Wetter 
et al 1999). In addition, in 16 patients, pergolide produced 
improvements in sleep efﬁ  ciency (from 61% to 79%) and 
reduced PLM-I (from 48.9 to 14.5) (Earley et al 1998). 
Long-term (median duration of about 1 year) follow-up of 
22 patients from one of these trials, taking open-label per-
golide, suggested that its positive treatment effects on PLMs 
and sleep parameters were maintained for this time (Stiasny 
et al 2001). However, pergolide is an ergot-related dopamine 
agonist, and is therefore subject to safety concerns typical of 
ergot derivatives, such as the development of cardiac-valve 
disease (Pritchett et al 2002; Baseman et al 2004). A large 
(n=302), 6-month, open-label trial of cabergoline has dem-
onstrated improvements in patients’ symptoms of RLS and in 
their subjective sleep quality (Benes et al 2004), and a small 
study (n=9) showed a reduction in PLM-I (from 195.8 to 26.4; 
this measure is for all PLMs, not just those while asleep) and 
an increase in total sleep time (from 302.7 minutes to 379.0 
minutes) (Stiasny et al 2000). However, cabergoline, as an 
ergot-related dopamine agonist, may be subject to the same 
safety concerns as pergolide.
There are a few reports of small studies (one open-
label, two placebo-controlled) of the non-ergot dopamine 
agonist pramipexole. These have shown that pramipexole 
improved patients’ symptoms of RLS and their subjec-
tive ratings of sleep (Saletu et al 2002b; Stiasny-Kolster 
and Oertel 2004). In addition, these studies showed that 
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Figure 1 Adjusted mean change from baseline in domains of the Medical Outcomes Study Sleep Scale following treatment with ropinirole or placebo in patients with 
RLS, at week 12 last observation carried forward. Beneﬁ  ts are indicated by positive changes in sleep quantity and adequacy, and negative changes in sleep disturbance and 
somnolence. Pooled data are from three studies with similar design, TREAT RLS 1, 2 and US (Trenkwalder et al 2004; Walters et al 2004; Bogan et al 2006)a.
Adjusted mean treatment difference:
Sleep disturbance: –10.4; 95% CI: –13.4, –7.4; p0.001
Daytime somnolence: –4.6; 95% CI: –7.0, –2.2; p0.001
Sleep adequacy: 11.8; 95% CI: 8.3, 15.2; p0.001
Sleep quantity: 0.5 hours; 95% CI: 0.3, 0.7; p0.001
a In each individual study, adjusted mean treatment differences were in favor of ropinirole compared with placebo on all domains, except that statistical signiﬁ  cance was not 
reached for daytime somnolence in the TREAT RLS US study.
†p0.001.
Abbreviations: CI, conﬁ  dence interval; MOS, Medical Outcomes Study Sleep Scale.Neuropsychiatric Disease and Treatment 2006:2(4) 518
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pramipexole improved objective measures of sleep, and 
PLMs. In 10 patients, pramipexole was associated with a 
PLM-I of 1.7, compared with 68.0 for placebo (Montplaisir 
et al 1999). In a study of 11 patients, pramipexole, compared 
with placebo, reduced PLM-I (8.2 vs 35.0) and increased 
total sleep time (377.6 minutes vs 301.1 minutes) (Saletu 
et al 2002b). Similarly, in 17 patients, pramipexole reduced 
PLM-I (11.3 vs 73.3 for placebo), and increased total sleep 
time (374.5 minutes vs 215.4 minutes) and sleep efﬁ  ciency 
(77.1% vs 44.5%) (Stiasny-Kolster and Oertel 2004). As 
expected for a dopamine agonist, the main adverse events 
related to pramipexole in these trials were gastrointestinal 
effects, particularly nausea.
Gabapentin therapy
Gabapentin, an analog of gamma-aminobutyric acid, was 
compared with L-dopa in an open-label study involving 
patients with RLS secondary to renal disease (Micozkadioglu 
et al 2004). After 4 weeks’ treatment, both therapies improved 
symptoms of RLS, and sleep quality, latency, and duration. 
In addition, gabapentin produced statistically signiﬁ  cantly 
greater beneﬁ  ts than L-dopa on RLS symptoms, on sleep 
quality, latency, and disturbance. In a small (n=24) double-
blind comparison with placebo, in a group of patients most 
of whom had primary RLS, gabapentin produced statistically 
signiﬁ  cant reductions in the symptoms of RLS, in PLM-I 
(11.1 compared with 20.8 for placebo), and improvements 
in sleep time (6.0 hours vs 5.5 hours) and sleep efﬁ  ciency 
(84.7% vs 79.4%) (Garcia-Borreguero et al 2002). The most 
common adverse event during gabapentin in this trial treat-
ment was malaise.
Conclusions
Sleep problems are extremely common in patients with 
RLS. These sleep disturbances may result from a combina-
tion of the sensory symptoms of RLS and the presence of 
PLMs and PLMW. Subjective sleep disturbances, objective 
measures of sleep, and PLMs can all be improved by the 
standard treatment for primary RLS, dopamine-agonist 
therapy.
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